On Thursday, research acceleration specialist Intermolecular, Inc (IMI) reported its Q2 2013 earnings results. The company reported total revenues of $16.6 million, with $12.8 million derived from ongoing collaborative development programs (CDP) and $3.8 million derived from licensing and royalty revenue. Intermolecular also reported a net loss of $744,000 or $0.02/share on a GAAP basis. These statistics combined, the company was roughly in line with analyst estimates which set the expectation for $16.54 million in revenues and a loss of $0.01/share.
Intermolecular now trades with a market capitalization of $290 million according to the intraday price of $6.50 as of July 26, 2013. As of June 30, the company carried a cash balance of roughly $80 million...
Only subscribers can access this article, which is part of the PRO research library covering 3,625 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: